Secondary primary malignancies ‘rare’ after CAR T-cell immunotherapy
A US study shows a projected five-year cumulative incidence of 15.2% for solid and 2.3% for haematological malignancies in treated patients.
The incidence of secondary primary malignancy after anti-CD19 chimeric antigen receptor T-cell immunotherapy is very low, according to a study in Nature Medicine.
US researchers describe a case of T-cell lymphoma occurring three months after chimeric antigen receptor (CAR) T-cell immunotherapy for non-Hodgkin B-cell lymphoma, which was diagnosed from a thoracic lymph node identified during lung cancer surgery.
